£81.27

Springer Biology and Treatment of Leukemia and Bone Marrow Neoplasms: 181 (Cancer Treatment and Research, 181)

Price data updated today

View at Amazon

Price History & Forecast

Last 57 days • 57 data points

Historical
Generating forecast...
£95.16 £68.71 £74.48 £80.25 £86.02 £91.79 £97.57 01 March 2026 15 March 2026 29 March 2026 12 April 2026 26 April 2026

Price Distribution

Price distribution over 57 days • 5 price ranges

Days at Price
Current Price
1 day 2 days 16 days · current 32 days 6 days 0 8 16 24 32 £71-76 £76-81 £81-86 £86-90 £90-95 Days at Price

Price Analysis

Most common range: £86-90 (32 days, 56.1%)

Price range: £71 - £95

Price levels: 5 price ranges over 57 days

Description

Product Description This book provides a concise update on current understanding of the biology of acute and chronic leukemias and other bone marrow neoplasms, including myelodysplastic and myeloproliferative disorders, and explores new and emerging treatments. There is a particular focus on the molecular abnormalities that are drivers of leukemia and on their detection by modern molecular techniques. Knowledge of the ways in which genomic and metabolic abnormalities in the hematologic neoplasms affect prognosis and treatment decision making is reviewed. Detailed attention is devoted to targeted therapies, including novel drugs, and to potential targets for future drug development. In addition, readers find in-depth discussion of cellular and antibody-based immunotherapies as well as the role of hematopoietic stem cell transplantation in the treatment of leukemias and bone marrow malignancies. The book is of special interest for hematologists, oncologists, and cancer researchers; it is also of value for hematology trainees and medical students. From the Back Cover This book provides a concise update on current understanding of the biology of acute and chronic leukemias and other bone marrow neoplasms, including myelodysplastic and myeloproliferative disorders, and explores new and emerging treatments. There is a particular focus on the molecular abnormalities that are drivers of leukemia and on their detection by modern molecular techniques. Knowledge of the ways in which genomic and metabolic abnormalities in the hematologic neoplasms affect prognosis and treatment decision making is reviewed. Detailed attention is devoted to targeted therapies, including novel drugs, and to potential targets for future drug development. In addition, readers find in-depth discussion of cellular and antibody-based immunotherapies as well as the role of hematopoietic stem cell transplantation in the treatment of leukemias and bone marrow malignancies. The book is of special interest for hematologists, oncologists, and cancer researchers; it is also of value for hematology trainees and medical students. About the Author Guido Marcucci, MD, is Chair and Professor in the Department of Hematologic Malignancies Translational Science and Professor in the Department of Hematology and Hematopoietic Stem Cell Transplantation at City of Hope (COH) Comprehensive Cancer Center in California. He is also Director of the Gehr Family Center for Leukemia Research at COH. Dr. Marcucci has conducted basic, translational, and clinical research in myeloid malignancies. His research focus has been on discovery of basic mechanisms of leukemogenesis, novel therapeutic targets, epigenetic and genetic prognostic biomarkers, and new drug development for AML and MDS. He has chaired several phase I, II, and III clinical trials as both single- and multi-institution studies within the oncology cooperative group Alliance (formerly known as CALGB), for which he is currently Vice-Chair of the Leukemia Committee and Member of the Leukemia Correlative Science Committee. Dr. Marcucci has published over 300 papers in peer-reviewed journals and has been uninterruptedly funded by the National Cancer Institute since 2001.   Vinod Pullarkat, MD, MRCP, is Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope National Medical Center in Los Angeles, California. Dr. Pullarkat’s clinical expertise is in the treatment of acute leukemia and other bone marrow neoplasms, including the use of hematopoietic stem cell transplantation.  He received his medical degree from University of Calicut, India, and undertook fellowship training in Hematology/Oncology at the University of Southern California, following which he served as Faculty in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope Medical Center and at the University of Southern California. Dr. Pullarkat’s research focuses especially on the biolo

Product Specifications

Format
hardcover
Domain
Amazon UK
Release Date
10 October 2021
Listed Since
15 August 2020

Barcode

No barcode data available

Similar Products You Might Like

Hematopoietic Growth Factors in Oncology: 157 (Cancer Treatment and Research, 157)
95% match

Hematopoietic Growth Factors in Oncology: 157 (Cancer Treatment and Research, 157)

Springer

£155.05 18 Mar 2026
Blood Stem Cell Transplantation: 77 (Cancer Treatment and Research, 77)
95% match

Blood Stem Cell Transplantation: 77 (Cancer Treatment and Research, 77)

Springer

£355.02 07 Jan 2026
Bone Marrow Transplantation: 50 (Cancer Treatment and Research, 50)
94% match

Bone Marrow Transplantation: 50 (Cancer Treatment and Research, 50)

Springer

£166.60 26 Feb 2026
Bone Marrow Transplantation: 50 (Cancer Treatment and Research, 50)
94% match

Bone Marrow Transplantation: 50 (Cancer Treatment and Research, 50)

Springer

£149.44 10 Mar 2026
Springer - Advances in Biology and Therapy of Multiple Myeloma 2
94% match

Springer - Advances in Biology and Therapy of Multiple Myeloma 2

Springer

£107.43 01 Mar 2026
Targeted Therapy of Acute Myeloid Leukemia (Current Cancer Research)
94% match

Targeted Therapy of Acute Myeloid Leukemia (Current Cancer Research)

Springer

£110.29 12 Dec 2025
Chronic and Acute Leukemias in Adults: 26 (Cancer Treatment and Research, 26)
94% match

Chronic and Acute Leukemias in Adults: 26 (Cancer Treatment and Research, 26)

Springer

£149.65 14 Apr 2026
Springer Hematologic Cancers: Molecular Pathobiology to Therapy
94% match

Springer Hematologic Cancers: Molecular Pathobiology to Therapy

Springer

£113.48 20 Apr 2026
Advance in the Treatment of Pediatric Leukemia
94% match

Advance in the Treatment of Pediatric Leukemia

£59.98 08 Mar 2026
Acute Myeloid Leukemia (Hematologic Malignancies)
94% match

Acute Myeloid Leukemia (Hematologic Malignancies)

£92.25 08 Jan 2026
Manual of Hematopoietic Cell Transplantation and Cellular Therapies
94% match

Manual of Hematopoietic Cell Transplantation and Cellular Therapies

£151.93 13 Dec 2025
Cancer Stem Cell Resistance to Targeted Therapy: 19 (Resistance to Targeted Anti-Cancer Therapeutics, 19)
94% match

Cancer Stem Cell Resistance to Targeted Therapy: 19 (Resistance to Targeted Anti-Cancer Therapeutics, 19)

Springer

£75.84 28 Feb 2026
Hematologic Malignancies: An Overview - Hematology Research
94% match

Hematologic Malignancies: An Overview - Hematology Research

Out of Stock 17 Apr 2026
Cancer Stem Cells: New Horizons in Cancer Therapies
94% match

Cancer Stem Cells: New Horizons in Cancer Therapies

Springer

£76.73 23 Feb 2026
Pharmaceutical Perspectives of Cancer Therapeutics
94% match

Pharmaceutical Perspectives of Cancer Therapeutics

Springer

£139.95 11 Jan 2026
Blood and Marrow Transplantation Long Term Management: Survivorship after Transplant
94% match

Blood and Marrow Transplantation Long Term Management: Survivorship after Transplant

Wiley-Blackwell

£105.41 22 Apr 2026
Handbook of Hematologic and Oncologic Emergencies
94% match

Handbook of Hematologic and Oncologic Emergencies

Springer

£50.01 25 Apr 2026
Treatment of Leukemia and Lymphoma (Volume 51) (Advances in Pharmacology, Volume 51)
94% match

Treatment of Leukemia and Lymphoma (Volume 51) (Advances in Pharmacology, Volume 51)

Academic Press

£175.00 04 Mar 2026
Multiple Myeloma: 183 (Recent Results in Cancer Research, 183)
94% match

Multiple Myeloma: 183 (Recent Results in Cancer Research, 183)

Springer

£84.29 08 Mar 2026
Resistance to Targeted Therapies in Lymphomas: 21 (Resistance to Targeted Anti-Cancer Therapeutics, 21)
94% match

Resistance to Targeted Therapies in Lymphomas: 21 (Resistance to Targeted Anti-Cancer Therapeutics, 21)

Springer

£76.09 23 Apr 2026
Resistance to Targeted Therapies in Lymphomas: 21 (Resistance to Targeted Anti-Cancer Therapeutics, 21)
94% match

Resistance to Targeted Therapies in Lymphomas: 21 (Resistance to Targeted Anti-Cancer Therapeutics, 21)

Springer

£65.04 28 Feb 2026
A Guide to Bone Marrow Transplantation
94% match

A Guide to Bone Marrow Transplantation

Springer

£99.40 21 Apr 2026
Cord Blood Transplantations (Advances and Controversies in Hematopoietic Transplantation and Cell Therapy)
94% match

Cord Blood Transplantations (Advances and Controversies in Hematopoietic Transplantation and Cell Therapy)

Springer

£86.01 26 Feb 2026
Leukemia Stem Cells in Hematologic Malignancies: 1143 (Advances in Experimental Medicine and Biology, 1143)
94% match

Leukemia Stem Cells in Hematologic Malignancies: 1143 (Advances in Experimental Medicine and Biology, 1143)

Springer

£103.97 07 Mar 2026